Pembrolizumab Plus Lenvatinib Earns Priority Review in 2 ... | 合法藥品大搜索

由 R Motzer 著作 · 2021 · 被引用 68 次 — The finding of an overall survival benefit of lenvatinib in combination with pembrolizumab but not in combination with everolimus confirms that an ... Read More

由 V Makker 著作 · 2019 · 被引用 200 次 — Lenvatinib is a multikinase inhibitor of VEGFR1, VEGFR2, and VEGFR3, and other receptor tyrosine kinases. Pembrolizumab, an antibody ... Read More

由 V Makker 著作 · 2020 · 被引用 92 次 — Lenvatinib plus pembrolizumab showed promising antitumor activity in patients with advanced endometrial carcinoma who have experienced ... Read More

由 R Motzer 著作 · 2021 · 被引用 68 次 — Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. N Engl J Med. 2021 Apr 8;384(14):1289-1300. doi: ... Read More

2021年4月10日 — Pembrolizumab at 200 mg intravenously every 3 weeks for up to 35 cycles in combination with lenvatinib at 20 mg orally once daily); lenvatinib ... Read More

2021年3月20日 — Lenvatinib/pembrolizumab showed a statistically significant and clinically meaningful improvement in overall survival, progression-free survival, ... Read More

2021年3月19日 — ... and overall survival benefit, data for the pembrolizumab/lenvatinib combination were presented at the Society of Gynecologic Oncology 2021 ... Read More

2021年5月6日 — Pembrolizumab Plus Lenvatinib Earns Priority Review in 2 Disease Indications ... In the advanced treatment setting, an FDA decision has indicated ... Read More

2020年3月13日 — Lenvatinib plus pembrolizumab showed promising antitumor activity in patients with advanced endometrial carcinoma who have experienced ... Read More

由 TH Chen 著作 · 2021 · 被引用 1 次 — In this study, we presented our up-to-date experience with pembrolizumab/​lenvatinib combination therapy in heavily pretreated R/M HNSCC. Methods: Patients ... Read More